Now that 2025 has come to an end, I want to take the opportunity to reflect on a year of meaningful progress for our company and for the broader clinical research community we serve.
This past year marked a tremendous period of evolution for Ametris, shaped by a shared goal of advancing the thoughtful and rigorous use of digital health technologies in clinical research to help people live longer, healthier lives.
Expanding Our Platform Capabilities
In January, we acquired the Biofourmis Connect platform. Over the course of the year, our teams focused on the technical integration of Connect with our existing technology ecosystem, including the Algorithm Marketplace and our operational model for scaling data collection into pharmaceutical trials. Together, this enhanced technology platform supports high-quality evidence generation across a wide range of therapeutic areas. For sponsors and researchers, this approach offers more options and flexibility, while reducing implementation risk and preserving scientific rigor.
Advancing Digital Evidence in Oncology
We also continued to deepen our work in digital evidence generation, particularly in oncology. Our involvement in cancer cachexia research, including the Pfizer ponsegromab Phase 2 study, highlighted the value of digital measures in capturing aspects of physical function that are difficult to assess through patient-reported outcomes alone. This work has informed important discussions around endpoint selection, patient burden, and sponsor decision-making. With experience across 16 industry-sponsored oncology trials, we have gained valuable insights into how wearable technologies can be integrated effectively into oncology study designs.
Collaboration Through the DECODE Model
Collaboration remained a central theme in 2025. In October, we launched our second DECODE working group, DECODE Obesity, in partnership with Roche, Eli Lilly and Company, Novo Nordisk, and AstraZeneca. Building on the DECODE model, this initiative aims to strengthen clinical programs in obesity with mature, well-validated assessments of physical activity and function by bringing together sponsors to generate clinical evidence, engage regulators, and develop evidence-based frameworks for the use of digital measures.
Advancing Scientific Exchange With ADDS
We also continued to invest in scientific exchange and community building through our ADDS conferences. In February, we hosted our third annual ADDS meeting in Pensacola Beach, and in November we brought ADDS to Europe for the first time with ADDS Basel. These meetings provide an important forum for pharmaceutical researchers, academic investigators, and digital health experts to share learnings, discuss challenges, and explore collaborations that advance the responsible adoption of digital measures.
A New Name Reflecting a Broader Role
And last, but certainly not least, in June we introduced our new company name, Ametris. This rebrand reflects the expanded scope of our technology platform, scientific capabilities, and our role in clinical research today. ActiGraph remains the brand name for our wearable devices, while Ametris represents our broader evolution into a scientific-driven, digital evidence generation partner for life science research. Although our name and visual identity have changed, our commitment to quality, service, and long-term partnerships remains exactly the same, grounded in more than two decades of experience supporting clinical research.
Looking Ahead to 2026
As we look ahead, our focus remains on continued collaboration and evidence generation. This includes ongoing work with DECODE Nocturnal Scratch and DECODE Obesity, as well as the launch of a new DECODE initiative. We look forward to convening the community again at ADDS 2026, which will be held Feb 23-25 in Atlanta for the first time. We will also continue to invest in product development to meet the evolving needs of our clients, with particular attention to supporting academic researchers alongside industry partners.
Thank you for your collaboration, trust, and continued engagement throughout 2025. We look forward to working together in the year ahead!
